We thank the patients who kindly agreed to participate in this study. Special thanks to Brigitte Jordan of GIZ and Alois Doerlemann of Health Focus GmbH for their invaluable help in planning and implementing the ESTHER partnership between the Regional Hospital Limbe and the Faculty of Medicine of the University of Rostock.
Chadwick DR, Sarfo FS, Kirk ES, Owusu D, Bedu-Addo G, Parris V, Owusu AL, Phillips R, 2015. Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol 16: 195.
Okafor UH, Unuigbe EI, Chukwuonye E, 2016. Prevalence and clinical and laboratory characteristics of kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in south-south Nigeria. Saudi J Kidney Dis Transpl 27: 129–134.
Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U, 2014. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 2: e174–e181.
FolefackKaze F, Kengne AP, PefuraYone EW, NdamFemben NS, Ashuntantang G, 2013. Renal function, urinalysis abnormalities and correlates among HIV-infected Cameroonians naive to antiretroviral therapy. Saudi J Kidney Dis Transpl 24: 1291–1297.
Mallipattu SK, Salem F, Wyatt CM, 2014. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int 86: 259–265.
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191–201.
Pozniak AL 2006. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes–a 96-week analysis. J Acquir Immune Defic Syndr 43: 535–540.
Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK, 2002. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 1257–1263.
Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M, 2011. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25: 1603–1609.
De Beaudrap P 2010. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 26: 1221–1227.
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, 2010. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667–1678.
Solomon MM 2014. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 28: 851–859.
Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, Brooks JT, 2007. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic) 6: 178–187.
Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D, 2010. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53: 62–69.
Labarga P 2009. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23: 689–696.
Gupta SK, 2009. Can the SMART study data be used to assess risk factors for renal disease? Ann Intern Med 150: 282, author reply 282–283.
Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA, 2009. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 10: 329–336.
Fux CA 2007. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165–1173.
Agbaji OO, Agaba PA, Idoko JA, Taiwo B, Murphy R, Kanki P, Ekong E, 2011. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians. West Afr J Med 30: 164–168.
Gupta SK 2005. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 1559–1585.
Kengne AP, Kaze FF, Dzudie A, Awah PK, Ngu KB, 2007. HIV/AIDS occurrence in the main university teaching hospital in Cameroon: audit of the 2001 activities of the service of internal medicine. J Int Assoc Physicians AIDS Care (Chic) 6: 61–65.
Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A, 2008. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 23: 741–746.
Fabian J, Naicker S, Venter WD, Baker L, Naidoo S, Paget G, Wadee S, 2009. Urinary screening abnormalities in antiretroviral-naive HIV-infected outpatients and implications for management—a single-center study in South Africa. Ethn Dis 19 (1 Suppl 1): S1-80-5.
Wools-Kaloustian K, Gupta SK, Muloma E, Owino-Ong’or W, Sidle J, Aubrey RW, Shen J, Kipruto K, Zwickl BE, Goldman M, 2007. Renal disease in an antiretroviral-naive HIV-infected outpatient population in western Kenya. Nephrol Dial Transplant 22: 2208–2212.
Obirikorang C, Osakunor DN, Ntaadu B, Adarkwa OK, 2014. Renal function in Ghanaian HIV-infected patients on highly active antiretroviral therapy: a case-control study. PLoS One 9: e99469.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150.
Garko SS, Ibinaiye PO, Abba SM, Ahmed A, Tanimu SS, Okere PC, 2015. The utilization of diagnostic ultrasound in the evaluation of the kidneys in HIV-associated nephropathy. West Afr J Radiol 22: 20–26.
Han TM, Naicker S, Ramdial PK, Assounga AG, 2006. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 69: 2243–2250.
Wyatt CM, Shi Q, Novak JE, Hoover DR, Szczech L, Mugabo JS, Binagwaho A, Cohen M, Mutimura E, Anastos K, 2011. Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. PLoS One 6: e18352.
Msango L, Downs JA, Kalluvya SE, Kidenya BR, Kabangila R, Johnson WD Jr, Fitzgerald DW, Peck RN, 2011. Renal dysfunction among HIV-infected patients starting antiretroviral therapy. AIDS 25: 1421–1425.
Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, Kigozi A, Buchacz K, Weidle PJ, 2008. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 74: 925–929.
Reid A 2008. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46: 1271–1281.
Ayokunle DS, Olusegun OT, Ademola A, Adindu C, Olaitan RM, Oladimeji AA, 2015. Prevalence of chronic kidney disease in newly diagnosed patients with human immunodeficiency virus in Ilorin, Nigeria. J Bras Nefrol 37: 177–184.
Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD, 2004. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18: 541–546.
Owiredu WK, Quaye L, Amidu N, Addai-Mensah O, 2013. Renal insufficiency in Ghanaian HIV infected patients: need for dose adjustment. Afr Health Sci 13: 101–111.
Medapalli RK 2012. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 60: 393–399.
Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O’Hare AM, 2007. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18: 2968–2974.
Kengne AP, Awah PK, Fezeu L, Mbanya JC, 2007. The burden of high blood pressure and related risk factors in urban sub-Saharan Africa: evidences from Douala in Cameroon. Afr Health Sci 7: 38–44.
Kinai E, Hanabusa H, 2005. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 19: 2031–2033.
Diana NE, Naicker S, 2016. Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis 9: 223–234.